Deucravacitinib Long-Term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program. J of Skin 2022, 6 (6), s48. https://doi.org/10.25251/skin.6.supp.48.